porcin
reproduct
respiratori
syndrom
viru
prrsv
caus
agent
contagi
diseas
character
reproduct
failur
sow
respiratori
diseas
piglet
infecti
diseas
result
signific
loss
swine
industri
specif
antiprrsv
drug
need
studi
evalu
novel
class
antisens
compound
peptideconjug
phosphorodiamid
morpholino
oligom
ppmo
abil
suppress
prrsv
replic
cell
cultur
ppmo
analog
singlestrand
dna
contain
modifi
backbon
confer
highli
specif
bind
rna
resist
nucleas
six
ppmo
test
one
sequenc
complementari
termin
nucleotid
prrsv
genom
found
highli
effect
reduc
prrsv
replic
specif
dosedepend
manner
cell
cultur
treatment
gener
log
reduct
infecti
prrsv
yield
control
ppmo
effect
viral
titer
immunofluoresc
assay
antiprrsv
monoclon
antibodi
confirm
titer
observ
sequencespecif
effect
confirm
part
cellfre
luciferas
report
assay
system
show
inhibit
translat
decreas
targetrna
contain
mispair
relat
ppmo
realtim
rtpcr
show
product
prrsv
negativesens
rna
reduc
ad
cell
h
postviru
inocul
cell
viabil
assay
detect
cytotox
within
concentrationrang
studi
result
indic
ppmo
potenti
antiprrsv
agent
suppress
porcin
reproduct
respiratori
syndrom
viru
replic
morpholino
antisens
oligom
porcin
reproduct
respiratori
syndrom
prr
contagi
viral
diseas
caus
heavi
econom
loss
swine
industri
even
though
vaccin
commerci
avail
year
caus
agent
prrsv
envelop
singlestrand
rna
viru
famili
arterivirida
includ
equin
arter
viru
eav
lactat
dehydrogenaseelev
viru
ldv
mice
simian
hemorrhag
fever
viru
shfv
meulenberg
et
al
arterivirus
genom
organ
replic
process
similar
coronavirus
featur
positivesens
rna
genom
kb
code
sequenc
nonstructur
protein
preced
structur
protein
eight
open
read
frame
orf
identifi
prrsv
genom
orf
compris
viral
genom
sequenc
encod
viral
rna
replicas
meulenberg
et
al
prrsvinfect
cell
set
six
seven
nest
viral
subgenom
rna
form
conzelmann
et
al
meng
et
al
meng
et
al
meulenberg
et
al
subgenom
rna
ident
leader
sequenc
deriv
end
genom
rna
well
ident
termin
sequenc
preced
poli
tail
variabl
length
cotermin
ident
mrna
speci
gener
process
known
discontinu
subgenom
mrna
synthesi
sawicki
sawicki
van
marl
et
al
analysi
prrsv
genom
sequenc
two
genotyp
prrsv
recogn
north
american
european
ident
nucleotid
level
meng
et
al
genotyp
turn
contain
number
viral
strain
end
subgenom
mrna
north
american
strain
contain
common
leader
sequenc
base
nelsen
et
al
wherea
prototyp
strain
european
prrsv
genotyp
lelystad
viru
leader
base
meulenberg
et
al
north
american
european
genotyp
termin
untransl
region
sequenc
base
respect
exclud
poli
tail
common
subgenom
mrna
prrsv
subgenom
rna
polycistron
structur
believ
first
open
read
frame
orf
translat
viral
protein
meng
et
al
prrsv
propag
african
green
monkey
kidney
cell
cell
deriv
thereof
marc
benfield
et
al
horsfield
et
al
kim
et
al
meng
et
al
recent
strategi
control
prrsv
infect
success
attenu
live
viru
vaccin
commerci
avail
year
howev
outbreak
prr
result
viral
strain
nearli
ident
sequenc
vaccin
strain
report
opriessnig
et
al
outbreak
atyp
acut
prr
vaccin
pig
rais
seriou
concern
efficaci
current
vaccin
meng
made
clear
need
develop
altern
strategi
specif
efficaci
antivir
compound
would
consid
welcom
complement
vaccin
prr
control
studi
peptideconjug
phosphorodiamid
morpholino
oligom
ppmo
evalu
abil
block
prrsv
propag
cell
cultur
phosphorodiamid
morpholino
oligom
pmo
structur
similar
singlestrand
dna
oligonucleotid
approxim
base
length
contain
purin
pyrimidin
base
dna
pmo
differ
backbon
dna
howev
morpholin
ring
replac
deoxyribos
sugar
phosphorodiamid
linkag
replac
phosphodiest
linkag
fig
schmajuk
et
al
summerton
summerton
weller
pmo
uncharg
watersolubl
highli
resist
nucleas
degrad
hudziak
et
al
nelson
et
al
pmo
bind
target
mrna
watsoncrick
base
pair
exert
antisens
effect
prevent
access
critic
segment
rna
sequenc
translat
initi
site
steric
blockad
distinctli
differ
process
rnase
hdepend
mechan
induc
oftenus
antisens
structur
type
phosphorothio
dna
summerton
number
studi
shown
pmo
effect
specif
block
translat
target
mrna
vitro
vivo
arora
et
al
b
brent
drapeau
hudziak
et
al
qin
et
al
stein
et
al
taylor
et
al
shown
pmo
conjug
short
argininerich
peptid
ppmo
significantli
higher
effici
deliveri
cultur
cell
nonconjug
pmo
moulton
et
al
nelson
et
al
sequencespecif
antivir
efficaci
pmo
compound
vitro
document
calicivirus
stein
et
al
hepat
c
viru
rna
mccaffrey
et
al
mous
hepat
viru
neuman
et
al
sar
coronaviru
neuman
et
al
eav
van
den
born
et
al
sever
flavivirus
dea
et
al
kinney
et
al
experi
describ
report
demonstr
ppmo
design
target
region
prrsv
genom
inhibit
prrsv
replic
cell
cultur
sequencespecif
dosedepend
manner
cell
line
atcc
meng
et
al
maintain
dmem
medium
supplement
fetal
bovin
serum
cell
number
count
hemocytomet
cell
viabil
assess
trypan
blue
exclus
prrsv
strain
atcc
meng
et
al
lelystad
meulenberg
et
al
nvsl
nvsl
ame
ia
use
inocul
cell
multipl
infect
moi
pmo
test
viru
titrat
dilut
viru
ad
monolay
cell
plate
degre
cytopath
effect
cpe
character
cell
round
clump
detach
assess
microscop
h
prrsv
inocul
comparison
mockinfect
cell
tissu
cultur
infecti
dose
tcid
per
millilit
calcul
base
upon
cpe
develop
accord
method
reed
muench
describ
previous
meng
et
al
ifa
carri
report
previous
zhang
et
al
nucleocapsid
n
specif
monoclon
antibodi
nelson
et
al
specif
reaction
nprotein
detect
goat
antimous
iggfluorescein
isothiocyan
fitc
conjug
sigma
st
loui
mo
assess
fluoresc
microscopi
six
ppmo
complementari
specif
prrsv
rna
sequenc
design
ppmo
use
studi
target
site
locat
prrsv
tabl
depict
fig
pmo
synthes
avi
biopharma
inc
corval
method
previous
describ
summerton
weller
peptid
nh
rrrrrffrrrrcconh
design
r
f
r
coval
conjug
end
pmo
fig
conjug
purif
analysi
r
f
r
pmo
compound
refer
simpli
ppmo
report
similar
method
describ
elsewher
random
sequenc
ppmo
name
littl
agreement
prrsvor
primat
mrna
sequenc
also
util
control
nonsequencespecif
activ
chemistri
cell
seed
plate
cell
per
well
grown
overnight
experi
employ
viru
inocul
ppmo
treatment
viru
stock
dilut
cell
inocul
moi
h
incub
viru
inoculum
remov
ppmo
dilut
dmem
ad
cell
monolay
ppmo
includ
neg
control
dmem
without
ppmo
includ
mock
treatment
control
gentl
shake
cell
incub
h
pmo
solut
remov
mainten
medium
dmem
supplement
fb
ad
cell
incub
h
cell
cultur
supernat
cell
harvest
analysi
experi
employ
viru
inocul
post
ppmo
treatment
cell
monolay
first
treat
ppmo
manner
describ
h
ppmo
solut
remov
cell
inocul
viru
moi
h
incub
viru
inoculum
remov
mainten
medium
ad
cell
cultur
supernat
cell
harvest
analysi
h
postinocul
complementari
dna
oligonucleotid
synthes
includ
first
nucleotid
nt
untransl
region
utr
prrsv
genom
sequenc
ctaga
cgtat
aggtg
ttggc
tctat
g
oligom
subclon
upstream
luciferas
code
sequenc
promotercontain
report
plasmid
describ
previous
neuman
et
al
preluciferas
leader
sequenc
includ
nt
target
sequenc
ppmo
five
variant
ppmo
target
sequenc
contain
one
four
mismatch
also
synthes
subclon
luciferas
report
vector
dna
sequenc
conduct
confirm
leader
sequenc
seri
six
plasmid
plasmid
dna
linear
noti
downstream
prrsv
sequenceluciferas
fusion
region
vitro
transcript
conduct
megascript
kit
follow
manufactur
instruct
ambion
austin
tx
vitro
translat
carri
use
transcrib
rna
nucleasetr
rabbit
reticulocyt
lysat
promega
madison
wi
translat
reaction
mix
luciferas
assay
reagent
promega
accord
manufactur
instruct
data
collect
use
micropl
luminomet
biotek
instrument
inc
winooski
vt
rel
light
unit
produc
reaction
normal
mean
control
reaction
express
percent
inhibit
luciferas
translat
total
rna
isol
prrsvinfect
cell
use
trizol
reagent
follow
manufactur
instruct
invitrogen
carlsbad
ca
quantit
rtpcr
analysi
rna
treat
rnasefre
dnase
remov
dna
carryov
rna
isol
revers
transcrib
detect
negativesens
rna
revers
transcript
initi
forward
primer
gacgt
atagg
tgttg
consist
sequenc
ident
region
prrsv
genom
rna
prrsv
genom
rna
isol
virion
quantifi
use
gener
standard
curv
realtim
rtpcr
realtim
pcr
conduct
icycl
system
biorad
laboratori
hercul
ca
cdna
gener
negativesens
rna
primer
set
gtctg
tccct
agcac
gccct
ccgcc
ataaa
design
amplifi
sequenc
end
fulllength
negativesens
prrsv
antigenom
rna
iq
sybr
green
supermix
biorad
transcript
bactin
also
amplifi
sampl
order
assur
normal
quantit
rtpcr
detect
prrsv
rna
cell
viabil
cell
ppmo
treatment
determin
celltiterblu
promega
follow
manufactur
instruct
briefli
cell
treat
condit
ident
describ
ppmo
treatment
cell
mocktreat
cell
includ
comparison
celltiterblu
reagent
ad
incub
h
fluoresc
signal
measur
synergi
ht
multidetect
micropl
reader
biotek
assay
fluoresc
intens
reflect
number
viabl
cell
rel
percentag
fluoresc
intens
calcul
comparison
mocktreat
control
parallel
sequenc
align
two
major
genotyp
prrsv
show
part
utr
region
within
genotyp
highli
conserv
like
essenti
function
molecular
event
viral
life
cycl
tan
et
al
verheij
et
al
make
ration
target
antisens
pmo
design
studi
ppmo
design
sequenc
prrsv
virul
strain
north
american
genotyp
ppmo
target
site
select
common
leader
termin
sequenc
found
prrsv
genom
subgenom
rna
transcript
regulatori
sequenc
tr
region
translat
initi
region
end
negativesens
antigenom
rna
fig
six
ppmo
synthes
exact
basesequ
prrsv
rna
target
locat
list
tabl
ppmo
design
target
termin
nt
prrsv
genom
attempt
block
translat
design
target
genom
endregion
attempt
interfer
rna
synthesi
two
ppmo
design
trsregion
effort
interfer
prrsv
subgenom
rna
synthesi
andor
translat
trssgp
complementari
sequenc
immedi
upstream
includ
tr
target
trssgp
present
leader
genom
subgenom
rna
meng
et
al
nelsen
et
al
target
trsp
includ
tr
first
nt
complementari
sequenc
end
negativesens
prrsv
rna
design
intent
interf
synthesi
positivesens
prrsv
rna
complementari
sequenc
end
design
inhibit
translat
encod
protein
prrsv
replicas
complex
includ
rnadepend
rna
polymeras
virul
prrsv
strain
use
evalu
abil
variou
ppmo
inhibit
prrsv
replic
cell
moi
use
studi
reach
peak
replic
cell
around
h
postinocul
pi
initi
experi
ppmo
appli
cell
monolay
final
concentr
mm
dmem
incub
h
immedi
viru
inocul
period
cell
observ
daili
cpe
develop
supernat
collect
day
pi
viru
titrat
cell
determin
prrsv
level
six
ppmo
test
found
highli
effect
inhibit
prrsv
product
cell
treat
show
far
less
cpe
develop
cell
treat
mocktreat
fig
cell
treat
exhibit
somewhat
less
sever
cpe
control
four
ppmo
observ
effect
cpe
develop
titrat
prrsv
cell
cultur
supernat
show
treatment
reduc
viru
yield
compar
mock
treatment
fig
treatment
ppmo
gener
titer
similar
mock
treatment
confirm
cpe
observ
confirm
cpe
observ
obtain
conduct
ifa
cell
ppmo
treatment
subsequ
viru
inocul
ifa
monoclon
antibodi
prrsv
nprotein
show
treatment
led
far
fewer
fluorescentposit
cell
treatment
fig
indic
interf
prrsv
propag
fluoresc
foci
well
treat
mm
individu
posit
cell
well
treat
mm
treatment
result
nearli
cell
support
prrsv
replic
similar
mock
treatment
control
ppmo
treatment
also
conduct
postviru
inocul
similar
inhibitori
effect
cpe
develop
observ
avoid
possibl
ppmo
affect
viru
entri
cell
underw
virusadsorpt
period
begin
ppmo
treatment
remain
experi
unless
otherwis
specifi
found
effect
inhibitor
prrsv
replic
character
ppmo
doserespons
challeng
cell
inocul
inoculum
remov
ppmo
ad
cell
increment
concentr
mm
cell
cultur
supernat
harvest
h
later
titrat
prrsv
yield
prrsv
titer
reduc
concomitantli
increas
concentr
fig
demonstr
effect
doserespons
manner
effect
viru
replic
comparison
mocktreat
control
indic
antivir
action
sequencespecif
effect
next
test
effect
durat
ppmo
treatment
viral
propag
cell
monolay
inocul
viru
h
treat
mm
h
mainten
medium
replac
ppmo
solut
h
postinocul
cell
cultur
supernat
harvest
viru
titrat
viru
yield
cell
less
cell
treat
ppmo
h
respect
mocktreat
control
extens
treatment
time
past
h
lead
reduct
yield
experi
repeat
three
time
pattern
viru
yield
reduct
observ
time
increment
increas
ppmo
treatment
time
experi
result
correspond
increment
reduct
viral
titer
indic
uptak
timedepend
result
show
h
incub
requir
achiev
high
reduct
prrsv
replic
consequ
remaind
experi
report
herein
postinocul
immunofluoresc
assay
monoclon
antibodi
prrsv
show
green
fluoresc
indic
detect
prrsv
nucleocapsid
protein
infect
cell
ppmo
suppress
prrsv
replic
mm
ppmo
effect
ppmo
treatment
period
h
employ
unless
otherwis
specifi
apprais
persist
activ
ppmo
cell
time
inoculum
ad
cell
incub
h
h
commenc
h
ppmo
treatment
notic
less
cpe
develop
cell
receiv
viru
inocul
h
initi
ppmo
treatment
cell
inocul
h
ppmo
treatment
began
viru
titrat
show
viru
yield
sampl
inocul
h
post
ppmo
treatmentcommenc
less
respect
mocktreat
control
result
suggest
effect
ppmo
dilut
cell
metabol
growth
proceed
period
addit
fresh
ppmo
like
requir
maintain
high
antivir
activ
test
whether
could
effect
inhibit
preexist
prrsv
infect
commenc
ppmo
treatment
h
pi
fix
cell
h
pi
analysi
applic
led
reduc
prrsv
propag
time
point
compar
control
evidenc
ifa
analysi
show
fewer
fluorescentposit
cell
data
shown
timecours
number
prrsvposit
cell
increas
concert
delay
initi
treatment
result
demonstr
ppmo
treatment
commenc
time
earlier
h
prrsv
infect
cycl
effect
significantli
reduc
viru
amplif
degre
earlier
better
shown
inhibit
replic
doserespons
manner
scrutin
sequenc
specif
cellfre
report
assay
system
ppmo
bind
rna
target
translat
assay
result
translat
inhibit
downstream
luciferas
code
sequenc
increment
concentr
ppmo
ad
vitro
translat
reaction
determin
degre
translat
inhibit
extinct
concentr
ec
refer
amount
pmo
compound
requir
reduc
luciferas
signal
compar
untreat
control
obtain
ec
ppmo
rna
target
two
three
fourmismatch
higher
respect
compar
wildtyp
eg
zero
mismatch
target
ec
nm
respect
fig
result
demonstr
exhibit
less
inhibit
rna
target
contain
mismatch
among
two
rna
target
sequenc
contain
one
mismatch
nearli
twofold
less
activ
target
contain
mismatch
side
compar
mismatch
side
ec
nm
respect
fig
seri
report
translat
assay
confirm
sequencespecif
inhibit
targetrna
translat
show
three
four
mispair
ppmo
rna
target
markedli
reduc
duplex
sequenc
align
analysi
show
prrsv
strain
north
american
genotyp
use
experi
belong
exhibit
high
sequenc
conserv
termin
region
genom
strain
european
prrsv
genotyp
howev
differ
north
american
strain
region
lelystad
strain
prototyp
european
prrsv
nvsl
strain
second
north
american
prrsv
select
test
compar
effect
viral
replic
cell
cultur
cell
inocul
lelystad
nvsl
strain
ppmo
treatment
conduct
h
expect
treatment
mm
inhibitori
impact
replic
lelystad
strain
nvsl
manner
similar
data
shown
result
confirm
sequencespecif
inhibit
prrsv
propag
effect
postinfect
treatment
time
prrsv
rna
synthesi
ppmo
design
complementari
sequenc
termin
region
prrsv
genom
region
known
critic
preiniti
translat
van
den
born
et
al
suspect
ppmo
exert
antivir
effect
interf
translat
product
first
two
open
read
frame
prrsv
replicas
complex
expect
result
lower
level
replicas
protein
prrsv
rna
synthesi
would
ultim
reduc
investig
hypothesi
commenc
ppmo
treatment
multipl
time
point
pi
harvest
cell
h
pi
rna
isol
strandspecif
realtim
rtpcr
perform
measur
level
prrsv
negativesens
rna
indic
prrsv
rna
synthesi
pcr
result
show
applic
mm
h
pi
led
signific
reduct
negativesens
prrsv
rna
comparison
mm
mock
fig
vitro
translat
luciferas
report
assay
assess
ppmo
effect
variabl
target
sequenc
dna
version
complementari
target
sequenc
five
variant
target
sequenc
one
four
mismatch
mm
clone
upstream
luciferas
report
plasmid
rna
vitro
transcrib
vitro
translat
reaction
conduct
measur
luciferas
translat
six
rna
presenc
variou
concentr
ppmo
ec
shown
repres
effect
concentr
compound
result
reduct
luciferas
signal
compar
mock
treatment
control
b
rel
percentag
inhibit
calcul
comparison
mock
treatment
control
note
decreas
level
inhibit
luciferas
product
caus
ppmo
rna
increas
number
mispair
treatment
p
fig
applic
h
pi
result
differ
compar
mock
treatment
result
indic
treatment
led
decreas
prrsv
minusstrand
rna
synthesi
treatment
commenc
h
pi
cell
viabil
assay
conduct
order
assess
cytotox
ppmo
exclud
possibl
reduct
viru
yield
due
reduct
cell
viabil
cell
treat
mm
condit
ident
doserespons
experi
experi
repeat
twice
four
replic
averag
rel
effect
compar
control
cell
treat
mm
cell
treat
mm
percentag
viabl
cell
nearli
ident
mocktreat
cell
demonstr
ppmo
cytotox
mm
condit
ppmo
studi
design
target
highli
conserv
sequenc
utr
genom
subgenom
rna
north
american
prrsv
genotyp
total
six
antisens
ppmo
test
one
found
highli
effect
inhibit
prrsv
replic
cell
cultur
viru
titrat
ifa
result
demonstr
ppmo
effect
doserespons
sequencespecif
manner
reason
ineffect
five
ppmo
unclear
could
includ
inabl
certain
ppmo
access
complementari
prrsv
target
sequenc
success
ppmo
targetrna
duplex
ultim
affect
prrsv
replic
former
specul
support
secondari
structur
analysi
rna
fold
program
extens
stemloop
structur
prrsv
utr
predict
van
den
born
et
al
latter
specul
suggest
success
pmo
duplex
particular
prrsv
targetrna
site
simpli
could
caus
signific
interfer
critic
event
viral
life
cycl
translat
rna
synthesi
antisens
ppmo
eav
close
relat
arteriviru
van
den
born
et
al
sar
fellow
nidoviru
neuman
et
al
design
target
respect
trsregion
show
substanti
antivir
activ
studi
two
ppmo
target
prrsv
trsregion
ineffect
indic
particular
compound
unabl
significantli
interfer
process
prrsv
rna
synthesi
translat
van
den
born
et
al
also
found
sever
antisens
ppmo
target
differ
locat
utr
eav
high
antivir
activ
cell
cultur
van
den
born
et
al
studi
terminu
target
ppmo
show
antivir
activ
work
conduct
character
particular
ppmo
determin
whether
ppmo
capabl
act
inhibitor
translat
also
character
effect
mispair
targetrna
cellfre
luciferas
report
assay
studi
employ
vitro
transcriptiontransl
design
rna
targetsequ
modifi
contain
oneto
fourbas
mismatch
relat
ppmo
increment
less
inhibitori
effect
ppmo
evid
thu
provid
demonstr
ppmo
could
interfer
process
translat
inhibit
exert
compound
sequencespecif
fig
realtim
rtpcr
assess
negativesens
prrsv
rna
level
ppmo
appli
cell
variou
time
point
postviru
inocul
pi
cell
harvest
h
pi
total
rna
isol
strandspecif
realtim
rtpcr
perform
describ
section
result
clearli
indic
reduct
level
agreement
ppmo
rna
targetsequ
diminish
hybrid
affin
treatment
prrsvinfect
cell
mm
gener
low
detect
viru
yield
could
due
cell
littl
uptak
insuffici
quantiti
made
way
subcellular
locat
prrsv
replic
occur
specul
may
provid
potenti
explan
higher
ppmo
concentr
requir
cultur
cell
need
cellfre
report
assay
achiev
equival
level
inhibit
targetrna
express
initi
evalu
ppmo
employ
pretreat
protocol
ie
cell
treat
ppmo
compound
viru
inocul
result
indic
ppmo
effect
reduc
prrsv
replic
remaind
experi
posttreat
procedur
perform
although
one
might
expect
higher
prssv
titer
reduct
cell
preload
ppmo
comparison
posttreat
cell
find
case
sever
experi
show
stronger
prrsv
titer
reduct
posttreat
cell
log
comparison
pretreat
log
specul
peptid
portion
ppmo
compound
could
assist
viru
entri
pretreat
cell
likewis
suggest
van
den
born
et
al
ppmo
experi
eav
van
den
born
et
al
viru
particl
inoculum
may
adher
surfac
cell
pretreat
ppmo
surfac
nonpretr
cell
therefor
cell
pretreat
ppmo
may
engend
viru
entri
replic
cell
posttreat
van
den
born
et
al
also
notic
high
concentr
certain
ppmo
appear
sometim
associ
increas
viru
titer
van
den
born
et
al
studi
cultur
cell
show
ppmo
treatment
commenc
h
pi
least
h
subsequ
incub
mm
necessari
significantli
lower
replic
compar
control
furthermor
substanti
less
inhibit
observ
ppmotreat
begun
h
pi
case
earlier
commenc
time
observ
consist
expect
mechan
action
ie
block
translat
rna
protein
ifa
detect
prrsv
nprotein
indic
addit
h
pi
result
reduct
prrsvposit
cell
h
pi
reduc
nprotein
synthesi
ifa
observ
may
due
interf
either
synthesi
translat
n
subgenom
rna
latter
specul
seem
like
n
subgenom
rna
possess
leader
sequenc
common
prrsv
subgenom
rna
includ
target
site
implic
event
preiniti
translat
arterivirus
van
den
born
et
al
realtim
rtpcr
sampl
taken
h
pi
show
applic
h
pi
led
reduct
viral
negativesens
rna
product
suggest
suppress
translat
prrsv
replicas
addit
h
pi
fail
reduc
level
negativesens
viral
rna
suggest
time
point
prrsv
replicas
product
reach
level
suffici
maintain
prrsv
rna
synthesi
cell
viabil
assay
cell
treat
concentr
includ
mm
detect
cytotox
indic
suppress
prrsv
replic
due
inhibit
prrsv
molecular
event
absenc
cytotox
effect
antivir
concentr
import
characterist
compound
potenti
vivo
applic
preval
prrsv
infect
swine
herd
high
current
strategi
control
infect
includ
vaccin
less
adequ
effect
meng
opriessnig
et
al
specif
antiprrsv
drug
need
complement
strategi
prrsv
prevent
control
consid
feasibl
ppmo
synthesi
investig
pharmacokinet
toxicolog
antivir
properti
ppmo
vivo
desir
